|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | |  |  | | --- | --- | | |  | | --- | | Graphical user interface, website  Description automatically generated | | | |  | | --- | | **BULLETIN**  **What Massachusetts COVID-19 Vaccine Providers Need to Know**  **Week of 10/6/2022** | | | **LATEST NUMBERS**   * As of 10/6/2022 **5,510,185** people in Massachusetts have been fully vaccinated.   **WHO TO VACCINATE**  **Everyone ages 6 months and older** should receive a COVID-19 **primary series** vaccination for the prevention of COVID-19. Monovalent mRNA vaccines (i.e., Moderna and Pfizer) and Novavax Vaccine are recommended.  **Children ages 5-11 years** are recommended to receive **1 monovalent mRNA booster** dose if eligible.  **Everyone ages 12 years and older** is recommended to receive **1 age-appropriate bivalent mRNA booster dose** regardless of primary series product and number of monovalent booster doses previously received.  The recommended schedule and use of each COVID-19 vaccine product approved under BLA or authorized under EUA varies by the age and immune status of the recipient. There are two vaccination schedules: one for [people who are not moderately or severely immunocompromised](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#not-immunocompromised) and one for [people who are moderately or severely immunocompromised](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#immunocompromised).  Vaccination providers should ensure the correct age-appropriate product is administered based on the recipient’s age on the day of vaccination ([Table 1](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#table-01)). Vaccine doses should be administered by the intramuscular route and in accordance with the recommended intervals for that age group. For guidance on timing of vaccination in specific situations, see [Transitioning from a younger to older age group](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#transitioning-younger-older), [Considerations for extended intervals for COVID-19 vaccine primary series doses](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#intervals-covid19-vaccine-primary-series), and [COVID-19 vaccination and SARS-CoV-2-infection](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#infection).  See Appendices B ([People who received COVID-19 vaccine outside the United States](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-b)) and C ([People who received COVID-19 vaccine as part of a clinical trial](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-c)) for recommendations for these populations.  **QUESTION OF THE WEEK**  Q: Can COVID-19 vaccine and influenza (flu) vaccine be given together?A: Yes. COVID-19 vaccine and influenza (flu) vaccine can be given together ([coadministered](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#coadministration-other-vaccines)). COVID-19 vaccines may be administered without regard to timing of other vaccines. This includes simultaneous administration of COVID-19 vaccine and other vaccines on the same day. However, there are [additional considerations](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#coadministration-other-vaccines) if administering COVID-19 vaccine and an [orthopoxvirus vaccine](https://www.cdc.gov/poxvirus/monkeypox/health-departments/vaccine-considerations.html). Routine annual influenza (flu) vaccination is [recommended](https://www.cdc.gov/flu/pdf/professionals/acip/acip-2022-23-summary-of-recommendations.pdf) for all persons aged 6 months and older who do not have contraindications. October is an [ideal time to vaccinate](https://www.cdc.gov/mmwr/volumes/69/rr/rr6908a1.htm?s_cid=rr6908a1_w#recommendationsfortheuseofinfluenzavaccines,2020%E2%80%9321) individuals for the flu. Refer to the [General Best Practice Guidelines for Immunization: Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP)](https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html) for additional information on [timing and spacing](https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/timing.html) of vaccines and [administration of multiple injections](https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html) at a single visit.  **BIVALENT VACCINE SUPPLY**  **Ample Supplies of both Moderna and Pfizer Bivalent COVID-19 Vaccine**  **There are ample supplies of both bivalent Moderna and Pfizer COVID vaccines**. We encourage all health care providers to be vaccinating in their practices and hosting clinics. **Sites with doses on hand that are not actively vaccinating may be prevented from ordering additional supply. Sites not using their current vaccine supply on hand may transfer to another site.** You can order up to a two week supply of vaccine and order as often as needed.  To project your vaccine needs, consider the following:   * What is the patient population your clinic is serving, i.e., workforce or a public clinic * What is your staff capacity for vaccination each day/week * What is your storage capacity to store doses * How many doses do you need for the next two weeks   As reminder, **provider sites can order above the ceiling limit posted in the MIIS**. A pop-up warning will appear; click okay to bypass the warning. It will move you to the next screen to review and confirm the shipping information; click okay. The order worklist will appear on the next screen. Please check the order status on the worklist. Ensure your order is in ‘Submitted to State’ status. Orders will be processed by Vaccine Unit staff within 24-48 hours. Once approved, orders are submitted to CDC the next morning before 9 AM. Once orders are submitted to CDC, orders cannot be canceled or modified.  To ensure there are no issues or delay with your vaccine order:   * Report administered doses to the MIIS * Review your inventory and process a storage and handling issue in the MIIS for expired or wasted vaccines.   Providers are strongly encouraged to offer flu vaccine in conjunction with bivalent booster doses.  If you have any questions or need assistance with placing a bivalent Pfizer COVID vaccine booster, please call the Vaccine Management Unit at 617-983-6828 or email at [dph-vaccine-managment@mass.gov](mailto:dph-vaccine-managment@mass.gov).  **WHAT TO KNOW THIS WEEK**  **Authorization and endorsement of updated, bivalent boosters**  On August 31, 2022, the [FDA authorized](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-moderna-pfizer-biontech-bivalent-covid-19-vaccines-use) both Moderna and Pfizer bivalent boosters.  On September 1, 2022, ACIP met and made recommendations for use of the bivalent boosters. These recommendations were [endorsed](https://www.cdc.gov/media/releases/2022/s0901-covid-19-booster.html) a short time later by CDC Director Rochelle Walensky.   * Individuals ages 12 years and older, including those who are moderately or severely immunocompromised, are recommended to receive 1 dose of the updated/bivalent vaccine at least two months after receipt of a primary series or prior monovalent booster dose. * Either Pfizer bivalent vaccine (12 years and older) or Moderna bivalent vaccine (18 years and older) can be used based on the patient's age at time of administration. * ACIP repealed its previous recommendations for administration of monovalent vaccine boosters for persons ages 12 years and older. The new bivalent booster recommendation replaces previous booster recommendations for this age group. **With the FDA approval of the updated boosters, the original COVID-19 vaccines are no longer approved as boosters for people ages 12 years and older.** * For children five through 11 years, the previous ACIP recommendation remains unchanged, and a monovalent booster continues to be recommended.   Updated COVID-19 boosters add Omicron BA.4 and BA.5 spike protein components to the current vaccine composition, helping to restore protection that has waned since previous vaccination by targeting variants that are more transmissible and immune-evading.  In the coming weeks, CDC also expects to recommend updated COVID-19 boosters for other pediatric groups. When data are available and FDA authorizes these other types of COVID-19 boosters, CDC will quickly move to help make them available in the United States.    The new vaccines will have the same storage and handling parameters as the original vaccine products.    [Pfizer-BioNTech COVID-19 Vaccines](https://urldefense.com/v3/__https:/www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/storage.html__;!!CUhgQOZqV7M!nRUoQQ3O0sXDsoGrcKqMZNaYlntqzHaLjaVFFHDNRBSX8TjPyGoFcmPD-tBZlBdXf0iARx3zc_y54hIzVRIvIryBSLlh89fgjg$)   |  |  | | --- | --- | | A glass beaker with a label  Description automatically generated with low confidence | * Ultra-cold freezer storage (-90°C to -60°C) until expiry * NO FREEZER STORAGE * Refrigerate (2°C to 8°C) up to 10 weeks without puncturing * Note that it says “Bivalent” on the label |     [Moderna COVID-19 Vaccines](https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/downloads/storage-summary.pdf)   |  |  | | --- | --- | | Diagram  Description automatically generated | * NO ULTRA-COLD FREEZER STORAGE * Freezer storage (-25°C to -15°C) until expiry * Refrigerate (2°C to 8°C) up to 30 days without puncturing * Note that it says “Bivalent” on the label |   **CDC has streamlined what it means to be “**[**up to date**](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html)**” with COVID-19 vaccines.**  With the arrival of updated boosters, CDC is reframing what it means to be up to date with COVID-19 vaccination. **You are up to date if you have completed a primary series and received the most recent booster dose recommended for you by CDC**.  **Four COVID-19 vaccines are currently approved under a BLA or authorized under an EUA by the FDA:**  The following COVID-19 vaccines, categorized into three [vaccine types](https://www.cdc.gov/vaccines/hcp/conversations/understanding-vacc-work.html), are currently approved under a BLA or authorized under an EUA by the U.S. FDA:   * [mRNA vaccines](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/mrna.html)   + Moderna COVID-19 Vaccine/SPIKEVAX and Moderna COVID-19 Vaccine, Bivalent   + Pfizer-BioNTech COVID-19 Vaccine/COMIRNATY and Pfizer-BioNTech COVID-19 Vaccine, Bivalent * [Protein subunit vaccine](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/proteinsubunit.html)   + Novavax COVID-19 Vaccine, Adjuvanted * [Adenovirus vector vaccine](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/viralvector.html)   + Janssen (Johnson & Johnson) COVID-19 Vaccine   None of the currently FDA-approved or FDA-authorized COVID-19 vaccines are live-virus vaccines.  For primary series vaccination, three monovalent COVID-19 vaccines (listed in alphabetical order by manufacturer), are recommended: Moderna, Novavax, and Pfizer. Bivalent mRNA vaccines are not authorized or approved at this time for primary series doses.  For booster vaccination, Moderna and Pfizer are recommended. A person’s eligibility for booster vaccination and the appropriate mRNA booster dose product to use (i.e., monovalent or bivalent) depends on age and primary series product.  Janssen COVID-19 Vaccine is authorized for adults ages 18 years and older in [certain limited situations](https://www.fda.gov/media/146304/download) due to safety considerations (see [Appendix A](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-a)).  **COVID-19 vaccine formulations currently approved or authorized in the United States**  This table is page 1 of the 5-page [Summary Document for Interim Clinical Considerations](https://www.cdc.gov/vaccines/covid-19/downloads/summary-interim-clinical-considerations.pdf)  Table  Description automatically generated  **Vaccines Formulations Available for Ordering**  **COVID Vaccine Available for ordering in the MIIS**  All providers enrolled Massachusetts COVID-19 Vaccine Program (MCVP) are able to place routine orders for all of the following COVID-19 vaccine formulations through the Massachusetts Immunization Information System (MIIS).  Table  Description automatically generated   |  |  | | --- | --- | | |  | | --- | |  | | | |  | | --- | | * Initial shipments of the Pfizer-BioNTech vaccine for children aged 6m–4 years may state “2y to <5y” or “6m to <5y” on the vial or carton labels. Please note that vials or cartons with labels that state “2y to <5y” can be used for children aged 6m through 4 years. * Pfizer-BioNTech vaccine vial labels and cartons may also state that a vial should be discarded 6 hours after the first dilution however as stated in the EUA Fact Sheet the timeframe for use post-dilution is actually 12 hours just like orange and gray cap Pfizer vaccine formulations.     **\*Please Note:** For pediatric practices that are currently not supplying the Pfizer 5-11 year old formulation due to logistical challenges please consider supplying the new Moderna 6-11 year old formulation as it comes in only 5 dose vials, requires no reconstitution, and can be stored in a standard freezer until expiration. | | | ***New* Vaccine Inventory Management**  Vaccine Inventory Management is critical to ensure expired or vaccines past the Beyond Use Date (BUD) are not used to administered to patients. Vaccine inventory should be checked daily. During the daily check (1) review and compare your physical inventory to your MIIS inventory, (2) process storage and handling issues in the MIIS for all wasted or expired doses. Vaccine orders may be canceled or reduced due to MIIS inventory showing high inventory or expired vaccines.  Process [a storage and handling problem](https://resources.miisresourcecenter.com/trainingcenter/Storage%20Handling%20Problem_2018_Mini%20Guide.pdf) in the MIIS for any expired or wasted vaccines.  **Reminder** **Expiry Date vs Beyond Use Date (BUD)**  The **expiration date** is set by the manufacturer and is the date by which the vaccine should be used. The expiration date assumes that the vaccine has been stored and handled according to the manufacturer’s guidance. Expiration dates cannot change based on how vaccine is being stored or when a vial is punctured. However, on occasion, the expiration date may be updated by the manufacturer as additional stability data become available.  **Beyond Use Date (BUD)** is the date of when the vaccine can no longer be used due to a change in storage temperature, reconstitution, puncturing the vial, etc. It is recommended to place a label with the BUD and the initials of the person making the calculation whenever a vaccine vial or box is moved to a different temperature storage unit, reconstituted, or had a vial punctured resulting in a chance in the BUD.  You can find BUD guidance and labels for [Moderna,](https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/downloads/storage-handling-label.pdf)[Novavax](https://www.cdc.gov/vaccines/covid-19/info-by-product/novavax/downloads/novavax-bud-tracking-labels.pdf), [Janssen](https://www.cdc.gov/vaccines/covid-19/info-by-product/janssen/downloads/janssen-storage-handling-label.pdf), and [Pfizer](https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/downloads/storage-handling-label.pdf) from the CDC’s U.S. COVID-19 Vaccine Product Information webpage.  **Watch for Expired Vaccine**  Providers should make it a practice to regularly check inventory for expired vaccine and immediately remove expired inventory to prevent it from being administered.  **Vaccine Expiration Date Lookup & Reference Information:**   * [Novavax Expiry Date Checker](https://urldefense.com/v3/__https:/us.novavaxcovidvaccine.com/hcp__;!!CUhgQOZqV7M!nRUoQQ3O0sXDsoGrcKqMZNaYlntqzHaLjaVFFHDNRBSX8TjPyGoFcmPD-tBZlBdXf0iARx3zc_y54hIzVRIvIryBSLmNfQafCQ$) * [Pfizer COVID-19 Vaccine Expiry Website](https://lotexpiry.cvdvaccine.com/) * [Moderna Vial Expiration Date Look-up Tool](https://urldefense.com/v3/__https:/www.modernatx.com/covid19vaccine-eua/providers/vial-lookup*vialLookUpTool__;Iw!!CUhgQOZqV7M!yGxVYV8BHtqcZ60FKi8HB3uTYxz3dJj1bcC-2OzWyfsACxpCz6nJTr6JC4lms1wWZFJCEE0%24) * [Janssen Expiration Date Lookup Tool](https://urldefense.com/v3/__https:/vaxcheck.jnj/__;!!CUhgQOZqV7M!yGxVYV8BHtqcZ60FKi8HB3uTYxz3dJj1bcC-2OzWyfsACxpCz6nJTr6JC4lms1wWIR4woRQ%24)     **Helpful Reference Materials**   * [At-A-Glance COVID-19 Vaccination Schedule](https://urldefense.com/v3/__https:/www.cdc.gov/vaccines/covid-19/downloads/COVID-19-vacc-schedule-at-a-glance-508.pdf__;!!CUhgQOZqV7M!nRUoQQ3O0sXDsoGrcKqMZNaYlntqzHaLjaVFFHDNRBSX8TjPyGoFcmPD-tBZlBdXf0iARx3zc_y54hIzVRIvIryBSLk60L2j3w$) (updated 9/6/2022)   A helpful pdf showing a graphic of the COVID-19 vaccine recommendations based on  primary series product, age, and immune status.   * [Summary Document for Interim Clinical Considerations](https://www.cdc.gov/vaccines/covid-19/downloads/summary-interim-clinical-considerations.pdf) (Updated 9/13/2022) * [Interim COVID-19 Immunization Schedule](https://www.cdc.gov/vaccines/covid-19/downloads/COVID-19-immunization-schedule-ages-6months-older.pdf) (Updated 9/7/2022) * [AAP’s Pediatric COVID-19 Vaccine Dosing Quick Reference Guide](https://urldefense.com/v3/__https:/downloads.aap.org/AAP/PDF/COVID*20Vaccine*20Dosing_Quick*20Reference.pdf__;JSUl!!CUhgQOZqV7M!nRUoQQ3O0sXDsoGrcKqMZNaYlntqzHaLjaVFFHDNRBSX8TjPyGoFcmPD-tBZlBdXf0iARx3zc_y54hIzVRIvIryBSLkQx_euEA$) (updated Sept 2022) * [Moderna COVID-19 Vaccine for Children who Transition from a Younger to Older Age Group](https://urldefense.com/v3/__https:/www.cdc.gov/vaccines/covid-19/downloads/Moderna-Child-Age-Transition-508.pdf__;!!CUhgQOZqV7M!nRUoQQ3O0sXDsoGrcKqMZNaYlntqzHaLjaVFFHDNRBSX8TjPyGoFcmPD-tBZlBdXf0iARx3zc_y54hIzVRIvIryBSLm835ogRw$) * [Pfizer-BioNTech for Children who Transition from a Younger to Older Age Group](https://urldefense.com/v3/__https:/www.cdc.gov/vaccines/covid-19/downloads/Pfizer-Child-Age-Transition-508.pdf__;!!CUhgQOZqV7M!nRUoQQ3O0sXDsoGrcKqMZNaYlntqzHaLjaVFFHDNRBSX8TjPyGoFcmPD-tBZlBdXf0iARx3zc_y54hIzVRIvIryBSLm3fhfIdw$) * [Vaccine administration errors and deviations (Appendix D)](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-d) * [FAQs for the Interim Clinical Considerations](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/faq.html) * [COVID-19 vaccination and SARS-CoV-2 infection](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#infection) * [People who received COVID-19 vaccine outside the United States (Appendix B)](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-b) * [People who received COVID-19 vaccine as part of a clinical trial (Appendix C)](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-c) * [Triage of people with a history of allergies or allergic reactions (Appendix E)](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-e)     **Standing Orders**   * Novavax (updated 9/7/2022)   <https://www.cdc.gov/vaccines/covid-19/info-by-product/novavax/downloads/novavax-standing-orders.pdf>   * CDC’s Moderna COVID-19 Vaccine info (including the standing orders below)   <https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/index.html>   * Moderna Blue cap with magenta bordered label – 6 months through 5 years of age   <https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/downloads/infant_standing-orders.pdf>   * Moderna Blue cap with purple-bordered label – 6 through 11 years of age   <https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/downloads/6-11-standing-orders.pdf>   * Moderna Red cap with blue-bordered label – 12 through 17 years of age   <https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/downloads/12-17-standing-orders.pdf>   * Moderna, Monovalent and Bivalent– 18 years of age and older (updated 9/22/2022)   <https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/downloads/standing-orders.pdf>  Table  Description automatically generated   * CDC’s Pfizer COVID-19 Vaccine info (including the standing orders below)   <https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/index.html>   * Pfizer Maroon Cap: 6 months through 4 years of age   <https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/downloads/infant-standing-orders.pdf>   * Pfizer Orange Cap: 5 through 11 years of age (updated 5/24/2022)   <https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/downloads/Pfizer_PED_StandingOrders.pdf>   * Pfizer Gray Cap, Monovalent and Bivalent: 12 years of age and older (updated 9/12/2022)   <https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/downloads/gray-cap-Pfizer-BioNTech-standing-orders.pdf>  Table  Description automatically generated with medium confidence    **Preparations and Administration Summaries**   * Novavax [https://www.cdc.gov/vaccines/covid-19/info-by-product/novavax/downloads/novavax-prep-admin-summary.pdf](https://urldefense.com/v3/__https:/www.cdc.gov/vaccines/covid-19/info-by-product/novavax/downloads/novavax-prep-admin-summary.pdf__;!!CUhgQOZqV7M!nRUoQQ3O0sXDsoGrcKqMZNaYlntqzHaLjaVFFHDNRBSX8TjPyGoFcmPD-tBZlBdXf0iARx3zc_y54hIzVRIvIryBSLmS8GIhaA$) * Pfizer <https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/downloads/vaccine-at-a-glance.pdf> * Moderna <https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/downloads/vaccine-at-a-glance.pdf>     **Information for parents and caregivers:**   * [[Stay Up to Date with COVID-19 Vaccines Including Boosters|](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html) CDC](https://urldefense.com/v3/__https:/www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/children-teens.html?CDC_AA_refVal=https*3A*2F*2Fwww.cdc.gov*2Fcoronavirus*2F2019-ncov*2Fvaccines*2Frecommendations*2Fadolescents.html__;JSUlJSUlJSU!!CUhgQOZqV7M!nRUoQQ3O0sXDsoGrcKqMZNaYlntqzHaLjaVFFHDNRBSX8TjPyGoFcmPD-tBZlBdXf0iARx3zc_y54hIzVRIvIryBSLkfB9jY2A$) * [Frequently Asked Questions about COVID-19 Vaccination in Children | CDC](https://urldefense.com/v3/__https:/www.cdc.gov/coronavirus/2019-ncov/vaccines/faq-children.html__;!!CUhgQOZqV7M!nRUoQQ3O0sXDsoGrcKqMZNaYlntqzHaLjaVFFHDNRBSX8TjPyGoFcmPD-tBZlBdXf0iARx3zc_y54hIzVRIvIryBSLl-eqIMAQ$) * [6 Things to Know about COVID-19 Vaccination for Children | CDC](https://urldefense.com/v3/__https:/www.cdc.gov/vaccines/covid-19/planning/children/6-things-to-know.html?CDC_AA_refVal=https*3A*2F*2Fwww.cdc.gov*2Fvaccines*2Fcovid-19*2Fplanning*2Fchildren*2F10-things-to-know.html__;JSUlJSUlJSU!!CUhgQOZqV7M!nRUoQQ3O0sXDsoGrcKqMZNaYlntqzHaLjaVFFHDNRBSX8TjPyGoFcmPD-tBZlBdXf0iARx3zc_y54hIzVRIvIryBSLn4H4jdWg$) * [V-safe After Vaccination Health Checker | CDC](https://urldefense.com/v3/__https:/www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/vsafe.html__;!!CUhgQOZqV7M!nRUoQQ3O0sXDsoGrcKqMZNaYlntqzHaLjaVFFHDNRBSX8TjPyGoFcmPD-tBZlBdXf0iARx3zc_y54hIzVRIvIryBSLnDCjkUdQ$) * [COVID-19 Vaccine: Frequently Asked Questions | American Academy of Pediatrics](https://urldefense.com/v3/__https:/www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/covid-19-vaccine-for-children/about-the-covid-19-vaccine-frequently-asked-questions/__;!!CUhgQOZqV7M!nRUoQQ3O0sXDsoGrcKqMZNaYlntqzHaLjaVFFHDNRBSX8TjPyGoFcmPD-tBZlBdXf0iARx3zc_y54hIzVRIvIryBSLn2BtygXA$) * <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/children-teens-disabilities.html> | | |  | | |  | | --- | |  | | |  | | |  | | --- | |  | | | |  | | --- | | **COVID-19 vaccination schedule for people who are NOT moderately or severely immunocompromised**  For primary series vaccination, Moderna, Novavax, and Pfizer COVID-19 vaccines are recommended; only monovalent vaccines are approved or authorized for primary series doses. The same vaccine product should be used for all doses of the primary series (see [Interchangeability of COVID-19 vaccine products](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#Interchangeability)).  For booster vaccination, Moderna and Pfizer are recommended. Recommendations vary based on age and primary series product. **People ages 12 years and older are recommended to receive 1 age-appropriate bivalent mRNA booster dose after completion of any FDA-approved or FDA-authorized monovalent primary series or previously received monovalent booster dose(s). This new booster recommendation replaces all prior booster recommendations for this age group.**Monovalent mRNA vaccines are no longer authorized as a booster dose for people ages 12 years and older.  Children ages 5–11 years are recommended to receive 1 monovalent mRNA booster dose if eligible (i.e., if a booster dose is FDA-authorized for use in a specified population).    **While this** [**graphic**](https://urldefense.com/v3/__https:/www.cdc.gov/vaccines/covid-19/downloads/COVID-19-vacc-schedule-at-a-glance-508.pdf__;!!CUhgQOZqV7M!nRUoQQ3O0sXDsoGrcKqMZNaYlntqzHaLjaVFFHDNRBSX8TjPyGoFcmPD-tBZlBdXf0iARx3zc_y54hIzVRIvIryBSLk60L2j3w$) **is a helpful visual, it does not include clinical details necessary for administering COVID-19 vaccines. For clinical detail see the** [**Clinical Considerations**](https://urldefense.com/v3/__https:/www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html__;!!CUhgQOZqV7M!nRUoQQ3O0sXDsoGrcKqMZNaYlntqzHaLjaVFFHDNRBSX8TjPyGoFcmPD-tBZlBdXf0iARx3zc_y54hIzVRIvIryBSLlcdmHTpg$) **and guidance for** [**people who are not immunocompromised**](https://urldefense.com/v3/__https:/www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html*not-immunocompromised__;Iw!!CUhgQOZqV7M!nRUoQQ3O0sXDsoGrcKqMZNaYlntqzHaLjaVFFHDNRBSX8TjPyGoFcmPD-tBZlBdXf0iARx3zc_y54hIzVRIvIryBSLlzh-FKmg$)  Graphical user interface  Description automatically generated with medium confidence | | | |  | | --- | |  | | | |  | | --- | | **Considerations for intervals for mRNA COVID-19 vaccine primary series**  **An 8-week interval may be optimal for people who are not moderately or severely immunocompromised and ages 6 months-64 years, especially for males ages 12–39 years.** COVID-19 vaccines are FDA-approved or FDA-authorized for a 3-week (Pfizer vaccine) or 4-week (Moderna vaccine) interval between the first and second dose. A 3- or 4-week interval continues to be the recommended interval for people who are moderately or severely immunocompromised, adults ages 65 years and older, and in situations when the fullest possible protection needs to be achieved sooner (e.g., increased concern about [COVID-19 community levels](https://urldefense.com/v3/__https:/www.cdc.gov/coronavirus/2019-ncov/science/community-levels.html__;!!CUhgQOZqV7M!nRUoQQ3O0sXDsoGrcKqMZNaYlntqzHaLjaVFFHDNRBSX8TjPyGoFcmPD-tBZlBdXf0iARx3zc_y54hIzVRIvIryBSLnC1H_DIA$) or an individual’s higher risk for severe disease).  mRNA COVID-19 vaccines are safe and effective at the FDA-approved or FDA-authorized intervals, but a longer interval may be considered for some populations. While absolute risk remains small, the risk for myocarditis is higher for males ages 12-39 years, and this risk might be reduced by extending the interval between the first and second dose. [Some studies](https://urldefense.com/v3/__https:/www.cdc.gov/vaccines/acip/meetings/downloads/slides-2022-02-04/11-COVID-Moulia-508.pdf__;!!CUhgQOZqV7M!nRUoQQ3O0sXDsoGrcKqMZNaYlntqzHaLjaVFFHDNRBSX8TjPyGoFcmPD-tBZlBdXf0iARx3zc_y54hIzVRIvIryBSLm2YAf_jw$) in adolescents (ages 12-17 years) and adults have shown the small risk of myocarditis associated with mRNA COVID-19 vaccines might be reduced and peak antibody responses and vaccine effectiveness may be increased with an interval longer than 4 weeks. Extending the interval beyond 8 weeks has not been shown to provide additional benefit. **In summary, an 8-week interval may be optimal for people who are not moderately or severely immunocompromised and ages 6 months-64 years, especially for males ages 12–39 years.**  **Transitioning from a younger to older age group**  CDC recommends vaccine recipients **receive the recommended age-appropriate vaccine product and dosage based on their age on the day of vaccination**. If a person moves from a younger age group to an older age group, once they qualify for the older age formulation, they should receive the vaccine product and dosage for the older age group.    FDA authorization does allow for dosing options for certain age transitions. These options are considered acceptable, as opposed to recommended. Since these options are acceptable, they are not considered vaccine administration errors and do not need to be reported to VAERS. For more detail see the [Pfizer-BioNTech COVID-19 Vaccine for Children who Transition from a Younger to Older Age Group](https://urldefense.com/v3/__https:/www.cdc.gov/vaccines/covid-19/downloads/Pfizer-Child-Age-Transition-508.pdf__;!!CUhgQOZqV7M!nRUoQQ3O0sXDsoGrcKqMZNaYlntqzHaLjaVFFHDNRBSX8TjPyGoFcmPD-tBZlBdXf0iARx3zc_y54hIzVRIvIryBSLm3fhfIdw$) and the [Moderna COVID-19 Vaccine for Children who Transition from a Younger to Older Age Group](https://urldefense.com/v3/__https:/www.cdc.gov/vaccines/covid-19/downloads/Moderna-Child-Age-Transition-508.pdf__;!!CUhgQOZqV7M!nRUoQQ3O0sXDsoGrcKqMZNaYlntqzHaLjaVFFHDNRBSX8TjPyGoFcmPD-tBZlBdXf0iARx3zc_y54hIzVRIvIryBSLm835ogRw$), and the [Clinical Considerations](https://urldefense.com/v3/__https:/www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html*timing-spacing-interchangeability__;Iw!!CUhgQOZqV7M!nRUoQQ3O0sXDsoGrcKqMZNaYlntqzHaLjaVFFHDNRBSX8TjPyGoFcmPD-tBZlBdXf0iARx3zc_y54hIzVRIvIryBSLl41SFlaw$).    **COVID-19 vaccination schedule for people who ARE moderately or severely immunocompromised**  People with immunocompromising conditions or people who take immunosuppressive medications or therapies are [at increased risk for severe COVID-19](https://urldefense.com/v3/__https:/www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html__;!!CUhgQOZqV7M!nRUoQQ3O0sXDsoGrcKqMZNaYlntqzHaLjaVFFHDNRBSX8TjPyGoFcmPD-tBZlBdXf0iARx3zc_y54hIzVRIvIryBSLkIiPeCZA$). Because the immune response following COVID-19 vaccination may differ in people who are moderately or severely immunocompromised at the time of vaccination, specific guidance for this population is provided.  For primary series vaccination, Moderna, Novavax, and Pfizer COVID-19 vaccines are recommended; only monovalent vaccines are approved or authorized for primary series doses. The same vaccine product should be used for all doses of the primary series (see [Interchangeability of COVID-19 vaccine products](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#Interchangeability)).  For booster vaccination, Moderna and Pfizer are recommended. Recommendations vary based on age and primary series product. **People ages 12 years and older are recommended to receive 1 age-appropriate bivalent mRNA booster dose after completion of any FDA-approved or FDA-authorized monovalent primary series or previously received monovalent booster dose(s). This new booster recommendation replaces all prior booster recommendations for this age group.** Monovalent mRNA vaccines are no longer authorized as a booster dose for people ages 12 years and older.  Children ages 5–11 years are recommended to receive 1 monovalent mRNA booster dose if eligible (i.e., if a booster dose is FDA-authorized for use in a specified population).  People who are or who become moderately or severely immunocompromised should follow the COVID-19 vaccination schedule according to their age and immune status at the time of eligibility for that dose. For example, people who become moderately or severely immunocompromised after completing a 2-dose mRNA primary series do not need additional primary doses; however, they should follow the schedule for people who are moderately or severely immunocompromised for the booster dose. For situations in which diminished vaccine efficacy is anticipated, see [Additional considerations](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#additional-considerations) for vaccination outside of the FDA and CDC dosing intervals on a case-by-case basis.  **While this** [**graphic**](https://urldefense.com/v3/__https:/www.cdc.gov/vaccines/covid-19/downloads/COVID-19-vacc-schedule-at-a-glance-508.pdf__;!!CUhgQOZqV7M!nRUoQQ3O0sXDsoGrcKqMZNaYlntqzHaLjaVFFHDNRBSX8TjPyGoFcmPD-tBZlBdXf0iARx3zc_y54hIzVRIvIryBSLk60L2j3w$) **is a helpful visual, it does not include clinical details necessary for administering COVID-19 vaccines. For clinical detail see the** [**Clinical Considerations**](https://urldefense.com/v3/__https:/www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html__;!!CUhgQOZqV7M!nRUoQQ3O0sXDsoGrcKqMZNaYlntqzHaLjaVFFHDNRBSX8TjPyGoFcmPD-tBZlBdXf0iARx3zc_y54hIzVRIvIryBSLlcdmHTpg$) **and guidance for** [**people who are immunocompromised**](https://urldefense.com/v3/__https:/www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html*immunocompromised__;Iw!!CUhgQOZqV7M!nRUoQQ3O0sXDsoGrcKqMZNaYlntqzHaLjaVFFHDNRBSX8TjPyGoFcmPD-tBZlBdXf0iARx3zc_y54hIzVRIvIryBSLmAPdO08g$)**.** | |   Graphical user interface  Description automatically generated   |  |  | | --- | --- | | |  | | --- | |  | |  |  |  | | --- | --- | | |  | | --- | | **CDC interactive tool for the public to assess if they are eligible for a booster dose of COVID-19 vaccine**  CDC has an interactive tool to help users identify whether they (or someone else) need to receive a booster dose of COVID-19 vaccine. The “Find Out When You Can Get Your Booster” tool asks a series of simple questions about age, immunocompromise, number and type of previous doses of COVID-19 vaccines, and how long ago they received the most recent vaccination. From these answers, the tool reports whether a first or second booster dose may be beneficial and presents considerations for when to receive it. Find the tool [here](https://urldefense.com/v3/__https:/www.cdc.gov/coronavirus/2019-ncov/vaccines/booster-shot.html*when-you-can-get-booster__;Iw!!CUhgQOZqV7M!nRUoQQ3O0sXDsoGrcKqMZNaYlntqzHaLjaVFFHDNRBSX8TjPyGoFcmPD-tBZlBdXf0iARx3zc_y54hIzVRIvIryBSLkqIhXZbA$).    **EUA Fact Sheets**  Once a new EUA Fact Sheet is issued, it must be used. Previous ones no longer contain accurate information. | | | |  | | --- | | * Novavax EUAscan be found on the FDA website[here](https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/novavax-covid-19-vaccine-adjuvanted) * Pfizer EUAs can be found on the FDA website [here](https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccines) * Moderna EUAscan be found on the FDA website[here](https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccines) * Janssen EUAscan be found on the FDA website[here](https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/janssen-covid-19-vaccine) | | | |  | | --- | | **RESOURCES & LEARNING OPPORTUNITIES**  **Moderna Education Sessions**   * 25-minute presentation followed by live Q&A, register [here](https://app.livestorm.co/moderna-na-medical/modernas-omicron-bivalent-booster-update) * Regional Medical Affairs Office Hours, register [here](https://app.livestorm.co/moderna-na-medical/moderna-office-hours-omicron-bivalent-boosters)   **Pfizer COVID-19 Vaccine Medical Updates** on Current & Immunization Site Training  Pfizer Vaccines US Medical Affairs continues to host frequent *Medical Updates & Immunization Site Training for All Providers.* Session topics include:   * Emergency use authorization of the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) as a single booster dose for individuals 12 years of age and older * Use of each currently authorized vaccine presentation, including storage, handling, preparation, and administration * Question and answer session   To access the training sessions, please visit: [https://www.pfizermedicalinformation.com/en-us/medical-updates](https://urldefense.com/v3/__https:/www.pfizermedicalinformation.com/en-us/medical-updates__;!!CUhgQOZqV7M!wnopdixLkKhCVeMjUiwcd-KVQVUN9jXipkisyDlTme9oe3pB9EYR1yJo7AhKgBWejq3FUBI%24)  **Novavax Office Hours**  Starting August 31, 2022, Novavax will begin a new series of weekly training webinars. Use this link to see dates and times, and to register: [**https://novav.ax/officehours**](https://urldefense.com/v3/__https:/novav.ax/officehours__;!!CUhgQOZqV7M!jZjsDBXpnyOQUOLw7QCoOEI4UISNGYDMJjLufV-CTqOTLX3jmq7FqIzeFSSzXVwbhuvgZDUttfvy_PCrDF2MLN_8og$)  **COVID-19 Vaccine Training Modules**  CDC’s four training modules (General Overview, Pfizer, Moderna, Janssen) can be found [here](https://urldefense.com/v3/__https:/www2.cdc.gov/vaccines/ed/covid19/__;!!CUhgQOZqV7M!nRUoQQ3O0sXDsoGrcKqMZNaYlntqzHaLjaVFFHDNRBSX8TjPyGoFcmPD-tBZlBdXf0iARx3zc_y54hIzVRIvIryBSLmgOEuTAw$).  **COVID-19 Vaccine Webinar Series**  CDC is offering a series of brief (15-20 minute) webinars addressing topics around COVID-19 vaccination. These interactive, web-based training modules offer a real-world perspective on different issues around COVID-19 vaccines. Topics range from routine clinical and vaccine safety information to guidance for on-site clinic vaccination activities and having conversations with vaccine recipients. Each webinar includes self-test practice questions and lists additional resources related to the topic discussed. The landing page for all mini webinars is here: <https://www.cdc.gov/vaccines/covid-19/training-education/webinars.html>  **Morbidity and Mortality Weekly Report**, better known as MMWR, is CDC’s primary publication for disseminating the science it produces. The staff at MMWR have launched a [landing page](https://urldefense.com/v3/__https:/www.cdc.gov/mmwr/covid19_vaccine_safety.html__;!!CUhgQOZqV7M!nRUoQQ3O0sXDsoGrcKqMZNaYlntqzHaLjaVFFHDNRBSX8TjPyGoFcmPD-tBZlBdXf0iARx3zc_y54hIzVRIvIryBSLmguNExOQ$) to help people find the latest information on COVID-19 vaccine effectiveness and safety.    **Recent CDC MMWRs**  September 16, 2022  • [Mortality Risk Among Patients Hospitalized Primarily for COVID-19 During the Omicron and Delta Variant Pandemic Periods — United States, April 2020–June 2022](https://www.cdc.gov/mmwr/volumes/71/wr/mm7137a4.htm?s_cid=mm7137a4_w)  **MDPH RESOURCES**  **Massachusetts Resources**   * COVID-19 vaccinations for [children ages 6 months to 4 years old](https://www.mass.gov/info-details/covid-19-vaccinations-for-children-ages-6-months-to-4-years-old) * COVID-19 vaccinations for [children ages 5-11](https://www.mass.gov/info-details/covid-19-vaccinations-for-children-ages-5-11) * COVID-19 vaccinations for [people ages 12-17](https://www.mass.gov/info-details/covid-19-vaccinations-for-people-ages-12-17) * COVID-19 [Vaccine Information](https://www.mass.gov/covid-19-vaccine) * COVID-19 [booster information](https://www.mass.gov/info-details/covid-19-booster-frequently-asked-questions) and [booster frequently asked questions](https://www.mass.gov/info-details/covid-19-booster-frequently-asked-questions) * Search for Vaccine locations: <https://vaxfinder.mass.gov/> * COVID-19 Vaccine Resource Line/2-1-1 is available for individuals who are unable to use Vaxfinder, or have difficulty accessing the internet. Available in English and Spanish and has translators available in approximately 100 additional languages. * COVID-19 Vaccine Training and Education Resources for Providers: <https://www.mass.gov/info-details/covid-19-vaccine-training-and-education-resources-for-providers> * [Multilingual COVID-19 Materials](https://www.mass.gov/resource/multilingual-covid-19-materials). Resources related to Coronavirus Disease 2019 (COVID-19) in multiple languages. Includes videos and printables on topics like vaccine safety, pregnancy and the vaccine, and FAQs.   **Immunization Division Main Number**  For questions about immunization recommendations, disease reporting, etc.  Phone: 617-983-6800 (24/7 MDPH Epi line)  Fax: 617-983-6840  Website: <https://www.mass.gov/topics/immunization>  **MIIS Help Desk**  Phone: 617-983-4335  Fax: 857-323-8321  Email questions to: [miishelpdesk@mass.gov](mailto:miishelpdesk@mass.gov)  Website: <https://www.mass.gov/massachusetts-immunization-information-system-miis>    **MDPH Vaccine Unit**  Phone: 617-983-6828  Email questions to: [dph-vaccine-management@mass.gov](mailto:dph-vaccine-management@mass.gov)  Website: <https://www.mass.gov/service-details/vaccine-management>  **COVID-19 Email Box**  Email questions to: [COVID-19-Vaccine-Plan-MA@mass.gov](mailto:COVID-19-Vaccine-Plan-MA@mass.gov) | | | | | |